BliNK Biomedical

BliNK Biomedical was a biopharmaceutical company specializing in the discovery of therapeutic monoclonal antibodies using its proprietary BliNK platform. The technology, B-lymphocyte INterrogation and Kinetic analysis, enabled the high-throughput screening of entire B-cell repertoires to identify rare antibodies with optimal pharmacological properties. The company's research focused on high-value targets in oncology and infectious diseases, including programs targeting CD38 and PD-1. Formed through a merger involving BliNK Therapeutics and the antibody discovery unit of LFB, the company operated out of Lyon, France, and Stevenage, United Kingdom. In 2017, BliNK Biomedical was acquired by Kymab to enhance Kymab's antibody discovery engine and pipeline.